ENVB - Company ID 0000890821
The table below shows Enveric Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.78M | $2.84M | $7.25M | $8.03M | $4.79M | $174.08K |
| SG&A | $5.79M |
Enveric Biosciences, Inc. reported annual revenue of $39.91M for fiscal year 2019. That is down 7.2% from $43.00M in fiscal 2018. Over the 7 fiscal years shown, annual revenue grew from $6.14M (FY 2014) to $39.91M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.45M |
| $8.85M |
| $11.61M |
| $20.50M |
| $5.32M |
| Operating income | -$8.77M | -$9.63M | -$16.45M | -$27.42M | -$64.62M | -$5.62M |
| Income tax | - | $8.93K | $28.91K | -$1.49M | -$7.45M | - |
| Net income | $12.10M | $9.60M | $17.50M | -$18.47M | -$48.98M | -$6.86M |
| EPS (diluted) | -$36.24 | -$228.48 | -$121.29 | -$13.00 | - | - |